It is still the only oral GLP-1 on the market for type 2 diabetes, and in 2025, semaglutide in a pill was approved in the US as first oral GLP-1 for weight management
Drawing on twenty-five years of clinical experience, nutrition expert Ian Marber shares evidence-backed guidance, simple day-to-day menu ideas and supplement advice to help you eat well when eating less
But your health and safety matter more than anything
Nausea and vomiting rates are actually slightly higher with the pill, largely due to the fasting requirement
Omega-3 fatty acid s support cardiovascular health and reduce inflammation
By Application By application, type 2 diabetes mellitus accounted for a share of 76.49% in the GLP-1 receptor agonist market, as GLP-1 receptor agonists are well established within diabetes treatment algorithms, supported by comprehensive reimbursement coverage and extensive real-world clinical utilization